Evidence map›Paper›PMID 36366359›Full record

ArticleVaccines2022

Designing of Peptide Based Multi-Epitope Vaccine Construct against Gallbladder Cancer Using Immunoinformatics and Computational Approaches.

Mukhtar Ahmad Dar, Pawan Kumar, Prakash Kumar, Ashish Shrivastava, Muneer Ahmad Dar, Richa Chauhan, Vinita Trivedi, Ashutosh Singh, Eshan Khan, Ravichandiran Velayutham and 1 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Frontiers in cellular and infection microbiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Mukhtar Ahmad DarDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur 844102, India.
Pawan KumarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur 844102, India.
Prakash KumarDepartment of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur 844102, India.
Ashish ShrivastavaTranslational Bioinformatics and Computational Genomics Research Lab, Department of Life Sciences, Shiv Nadar University, G.B. Nagar 201314, India.ORCID 0000-0003-4610-7957
Muneer Ahmad DarDivision of Biotechnology, Sher-e-Kashmir University of Agricultural Sciences and Technology Kashmir (SKUAST-K), Shuhama 191201, India.
Richa ChauhanDepartment of Radiotherapy, Mahavir Cancer Sansthan and Research Centre (MCSRC), Phulwarisharif Patna 801505, India.
Vinita TrivediDepartment of Radiotherapy, Mahavir Cancer Sansthan and Research Centre (MCSRC), Phulwarisharif Patna 801505, India.
Ashutosh SinghTranslational Bioinformatics and Computational Genomics Research Lab, Department of Life Sciences, Shiv Nadar University, G.B. Nagar 201314, India.
Eshan KhanDepartment of Cancer Biology and Genetics, The Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA.ORCID 0000-0001-9502-4264
Ravichandiran VelayuthamDepartment of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata 700054, India.
Sameer DhingraDepartment of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur 844102, India.ORCID 0000-0003-2537-8889
National Institute of Pharmaceutical Education and Research · INMahavir Cancer Institute and Research Centre · INSher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir · INShiv Nadar University · INNational Institute of Pharmaceutical Education and Research · INThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is an aggressive and difficult to treat biliary tract carcinoma with a poor survival rate. The aim of this study was to design a peptide-based multi-epitope vaccine construct against GBC using immunoinformatics approaches. Three proteins implicated in the progression of GBC were selected for B and T cell epitope prediction and the designing of the potential vaccine construct. Seven CTL, four HTL and six Bcell epitopes along with a suitable adjuvant were selected and connected using linkers for designing the vaccine construct. The secondary and tertiary models of the designed vaccine were generated and satisfactorily validated. A Ramachandran plot of the final 3D model showed more than 90% of the residues in allowed regions and only 0.4% in disallowed regions. The binding affinity of a vaccine construct with TLR 2, 3 and 4 receptors was assessed through molecular docking and simulation. The average numbers of hydrogen bonds for vaccine-TLR 2, 3 and 4 complexes in the simulation were 15.36, 16.45, and 11.98, respectively, and remained consistent over a 100 ns simulation period, which is critical for their function. The results of this study provide a strong basis for further evaluation through in vitro/in vivo experimental validation of the safety and efficacy of the designed vaccine construct.

Indexed as

antigenicityepitopeGBCimmunoinformaticsTLRvaccine

Identifiers

PMID36366359
PMCPMC9696659
OpenAlexW4308117992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.